Loading
Cancer Treatment · Journal article
International Journal of Pharmaceutics: X · July 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical study of a pH-responsive nanoparticle delivery system (BAM NPs) designed to amplify ferroptosis in breast cancer cells and xenograft models. The authors report an 83.11% tumor inhibition rate in vivo and mechanistic evidence of ROS accumulation and ferroptosis induction, but provide no safety data, direct comparator controls, or human evidence.
Preclinical in vitro and in vivo proof-of-concept study. Breast cancer cell lines and xenograft tumor models; specific cell lines, animal species, and numbers not stated.. Intervention: BAM NPs (artesunate-loaded bovine serum albumin nanoparticles with metal-polyphenol network coating); pH-responsive delivery system..
BAM NPs induced tumor inhibition rate of 83.11% in vivo BAM NPs depleted intracellular glutathione (GSH) and inactivated GPX4 to disrupt redox homeostasis Nanoparticles degraded under acidic conditions to release artesunate and Fe3+, initiating Fenton reaction-driven ROS accumulation
Safety, pharmacokinetics, and biocompatibility data not reported.
This is a laboratory-stage discovery with no direct application to human patients. Further development would require dose-escalation studies, toxicity assessment, and eventually clinical translation.
Preclinical proof-of-concept in cell and animal models showing a novel nanoparticle formulation induces ferroptosis and tumor inhibition, but lacks human efficacy data, safety characterization, and direct comparator controls.
As stated by the source record.
Quoted from the source exactly as published.
This is a laboratory-stage discovery with no direct application to human patients. Further development would require dose-escalation studies, toxicity assessment, and eventually clinical translation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Ferroptosis, an iron-dependent programmed cell death process driven by reactive oxygen species (ROS) accumulation, represents a promising therapeutic strategy for breast cancer. However, the efficacy of ferroptosis therapy in breast cancer is often compromised by insufficient intracellular levels of hydrogen peroxide (H2O2) and iron ions. To address these problems, we developed pH-responsive nanoparticles comprising a metal-phenolic network (MPN) shell and a bovine serum albumin (BSA) core for the delivery of artesunate (ART) (designated as BAM NPs). The designed BAM NPs aim to amplify oxidative stress and enhance ferroptosis-based therapy for breast cancer. Upon endocytosis by tumor cells, BAM NPs underwent degradation under acidic conditions to release ART and Fe3+. Subsequently, the reduction of Fe3+ to Fe2+ by glutathione (GSH) initiated the Fenton reaction, which led to aberrant accumulation of ROS. Meanwhile, the endoperoxide bridge of ART could be cleaved by Fe2+ to further generate carbon-centered radicals (·C). Furthermore, BAM NPs effectively deplete GSH via Fe3+/Fe2+ conversion to inactivate glutathione peroxidase 4 (GPX4), thereby disrupting redox homeostasis and increasing intracellular LPO levels. Both in vitro and in vivo experiments showed that BAM NPs significantly inhibited tumor cell proliferation by inducing robust ferroptosis in tumor cells, leading to a tumor inhibition rate of 83.11%. In summary, the constructed BAM NPs served as a promising tailored nanoplatform for augmenting ferroptosis therapy in breast cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.